Objective: To verify possible associations between adenosine aminohydrolase (ADA) and AMP-aminohydrolase (AMPDA) to E3 SUMO-protein ligase NSE2 (NSMCE2) in patients with renal stones. And to isolate, purify and characterize ADA in patients with renal stones and healthy group. Methods: A total of 60 renal stones patients and 50 control were enrolled in a case–control study. The blood urea, creatinine, uric acid, protein, albumin, ADA and AMPDA were measured by colorimetric tests. The serum NSMCE2 was measured by ELISA. Results: Serum ADA, AMPDA and specific activity of enzymes showed significant decrease (P < 0.05) in patients with renal stones compared to control group, mean levels of sera NSMCE2 and uric acid had a significant increase (P < 0.01 and P < 0.05, respectively) in patients compared to control group. Conclusions: The present study suggests that ADA, AMP deaminase and NSMCE2 can be used as a indicator to monitor the DNA damage and inflammation disorders in the patients with kidney stones.